Introduction
Semliki Forest virus (SFV) is an enveloped positive-sense RNA virus and is a member of the genus Alphavirus of the family Togaviridae; it is a minor human pathogen in Africa, usually causing no more than a mild febrile disease. The 11.4 kb SFV genome encodes nine proteins, four of which are nonstructural and form the viral replicase. The capsid protein encapsidates a single RNA molecule, while the envelope proteins E1, E2 and E3 form the spikes. E2 and E3 are formed from a precursor protein, p62, and E2 is known to be antigenic, containing both T-and B-cell epitopes. 1, 2 The SFV4 strain of SFV, derived from an infectious clone, is lethal when given intranasally to mice. Only a proportion of mice die, however, when infected intraperitoneally and less when the virus is administered subcutaneously (s.c.). 3 The SFV recombinant particle vector system induces the transient expression of heterologous proteins and consists of recombinant SFV (rSFV) virus-like particles (VLPs) capable of only one round of replication. The viral structural proteins are replaced in the vector by a multicloning site where the desired heterologous gene is inserted, forming a recombinant RNA molecule which also encodes the nonstructural genes of SFV, including a packaging signal. In the split helper system, the structural proteins are provided in trans by two separate helper RNAs encoding the capsid and envelope proteins, but which have no packaging signal. All three RNA molecules are transcribed from the appropriate plasmids and transfected by electroporation into BHK-21 cells, resulting in the production of rSFV VLPs into which only the recombinant RNA molecule containing the heterologous gene is packaged. 4, 5 Several plasmids with specific deletions have been produced from the pSP6-SFV4 infectious clone of SFV, which produces the SFV4 infectious virus. 6 One of these, pSFV-p62-6k, contains deletions of the capsid and E1 genes, and is used in this study to express the E2 protein and hence stimulate immunity. To construct VLPs expressing E2 (and E3 and 6k) we have used the packaging system for the SFV vector.
Since the development of the SFV vector system, rSFV VLPs have been employed as potential cancer therapy agents, 7 vaccines, 8, 9 and for the delivery of therapeutic genes to the central nervous system. 10 SFV and its derived vector have been shown to induce apoptosis in a variety of cell lines irrespective of the p53 status of the cell. 11, 12 This inherent cytopathogenicity has been exploited by direct intratumoral injection of human lung carcinoma xenografts in nu/nu mice with rSFV VLPs, 13 and has been enhanced by the expression of proapoptotic genes such as bax.
14 Additionally, rSFV VLPs have been employed in the expression of cytokines and tumourassociated antigens in order to enhance antitumour immune responses and inhibit angiogenesis. [15] [16] [17] [18] Phase I and II clinical trials are currently planned to use liposome-encapsulated SFV vectors in the treatment of several tumours, including glioblastoma multiforme. 19 The use of replication proficient oncolytic viruses is now re-emerging as a possibility for tumour therapy, and viruses have been described that grow preferentially in tumour cells. 20, 21 These replicating systems may generate host immune responses against the virus or vector. This may be advantageous for tumour therapy as it aids tumour cell destruction by the immune system. 22 Mutations in ras genes are involved in approximately 30% of all human malignancies, and of these, K-ras is the most affected. Ras proteins are involved in cellular differentiation, proliferation, and survival, acting as binary switches at nodes in signal transduction pathways, which are rendered constitutively active by point mutations. [23] [24] [25] One of the murine tumour models used in this study is the Kirsten murine sarcoma virus transformed BALB/3T3 cell line, K-BALB, which overexpresses K-ras and forms fast-growing syngeneic tumours in immunocompetent BALB/c mice after s.c. injection. 26, 27 In addition, the antitumoural effect of rSFVp62-6k VLPs and SFV4 was also examined using the murine colon carcinoma CT26 cell line, which also readily forms tumours of low immunogenicity in BALB/c mice following s.c. injection. 28, 29 In the experiments presented here, we show that cells from these two tumour models are susceptible to SFV4 and rSFV VLP-induced apoptosis, and that treatment of the tumours with rSFV-p62-6k VLPs or SFV4 infectious virus inhibits tumour growth. For both models, inhibition of tumour growth was enhanced by an anti-SFV immune response, which was augmented by prior immunization of mice with rSFV-p62-6k VLPs. It is concluded that these strategies may be suitable for the treatment of rapidly growing tumours by direct injection or perfusion.
Results
Effect of rSFV-p62-6k VLP and SFV4 infection on cell viability and proliferation
To assess the effect of rSFV VLP and SFV4 infectious virus infection on the tumour cell lines examined, the trypan blue exclusion ( Figure 1a ) and thymidine incorporation (Figure 1b) assays were employed for K-BALB cells and thymidine incorporation alone for CT26 cells (Figure 1c ). Cells were infected with rSFV-p62-6k VLPs, SFV4 or medium alone and sampled over a 5-day period.
For K-BALB cells, both assays yielded similar results with mock-infected controls initially growing rapidly before slowing at 48-72 h postinfection (h.p.i.) and with a marked cytopathic effect observed in all infected cells. Infection with rSFV-p62-6k VLPs resulted in a drop in proliferation in the first 24 h and the number of viable cells dropped to 9% of the control after 48 h. Higher levels of proliferation were detected between 72 h.p.i. and 120 h.p.i., and by 120 h.p.i. VLP infected monolayers were recovering with cell numbers approaching 40% of the control wells. SFV4 infection followed a similar pattern for the first 72 h but the cells failed to recover to the same extent, reaching only 7% of controls at 120 h.p.i. CT26 cells were more efficiently infected by rSFV VLPs than K-BALB cells (B90% at a multiplicity of infection of 100 compared to B40% for K-BALB, not shown), resulting in rapid cessation in cellular proliferation following infection. At 48 h.p.i with rSFV-p62-6k VLPs, proliferation was detected at a level of 8% of that in control wells, but no significant thymidine incorporation was observed at any subsequent timepoint or at any timepoint for SFV4 infected wells. Mock-infected cells proliferated rapidly during the initial 72 h.p.i. after which proliferation was not detected.
Induction of apoptosis and viral antigen expression
Fluorescently labelled caspase inhibitors were employed to assess apoptosis induction in infected K-BALB cells. Immunofluorescence was performed on cytospins of the same cells to detect expression of viral antigen and apoptosis induction (Figure 2 ). Cells were infected with rSFV-p62-6k VLPs, SFV4 or medium alone and sampled over a 3-day period. A low level of apoptosis was observed in mock-infected cells (Figure 3a ) which peaked at 48 h.p.i., approaching 4% before dropping again. Both rSFV-p62-6k VLPs and SFV4 induced expression of viral antigen and apoptosis (Figure 3b and c) with SFV4 displaying a more persistent effect than the VLPs. VLP infection resulted in an increase in detectable expression of viral antigen with 87% of cells positive at 36 h.p.i., after which the number of antigen positive cells began to fall. Apoptosis induction was apparent early with 5% of cells positive at 6 h.p.i. This remained constant until 24 h.p.i., when the number of active-caspase-positive cells began to increase, peaking at 48 h.p.i. at 43%. SFV4 infection resulted in a different pattern with high levels of viral antigen positive cells as early as 6 h.p.i., and from 12 h.p.i. the number of antigen positive cells remained higher than 85%. Apoptosis induction was detectable at 6 h.p.i. (13% of cells positive) but did not increase significantly until 36 h.p.i., when the number of active-caspase-positive cells reached 38% and remained at this level for the duration of the experiment. Thus, despite a relatively low transduction efficiency (B40% at a multiplicity of infection of 100, not shown) it is clear that K-BALB cells are susceptible to SFV induced apoptosis and express viral antigens efficiently upon infection with either rSFV-p62-6k VLPs or SFV4.
Treatment of K-BALB and CT26 tumours
Tumours were induced by s.c. injection of K-BALB or CT26 cells into the right flank of naïve and rSFV-p62-6k VLP immunized BALB/c and BALB/c nu/nu mice. The two types of tumour grew at similar rates. At 24 h postinduction with K-BALB cells, 33% of mice developed tumours with an average diameter of 4 mm and by 96 h postinduction 100% of mice had tumours of this size. As soon as tumour diameter reached 4 mm, a total of six 50 ml intratumoral injections were administered to each mouse with each injection administered every second day. Groups of five mice were treated with TNE buffer alone (control), TNE buffer containing 10 10 infectious units (IU)/ml rSFV-p62-6k VLPs, or TNE buffer containing 10 10 plaque-forming units (PFU)/ml SFV4. BALB/c nu/nu mice were not included in CT26 studies or SFV4 treatment experiments (due to the potentially lethal effect of infection with the latter) and no immunized mice succumbed to SFV4 infection. Only two of 47 naïve BALB/c mice treated with SFV4 showed clinical signs of infection (dullness, anorexia) commencing on day 4 postchallenge; these mice were in groups sampled for brain pathology and detection of replicating SFV4 in brains and were sampled accordingly on day 5.
Control tumours treated with buffer alone grew rapidly in both immunocompetent and nu/nu groups. By 25 days after initiation of treatment, all K-BALB control mice had been euthanized when the average diameter of the tumours reached 20 mm. There was no significant difference in tumour growth between BALB/c and BALB/c nu/nu mice. Mice bearing CT26 tumours were euthanized earlier due to ulceration of the tumours, so the end point for these mice was 15 mm. All control Figure 2 Detection of apoptosis induction and SFV antigen expression in K-BALB cells infected with SFV4. After infection with SFV4, cells were incubated with fluorescently labelled caspase inhibitor (green); cytospins were subsequently stained for SFV antigen (red) using immunofluorescence and nuclei were counterstained with DAPI (blue). Cells still maintained normal morphology with intact nuclei at 6 h.p.i.; activated caspase can be seen to be located in the cytoplasm and nucleoli (a). By 36 h membrane blebbing was apparent and nuclei were condensed and fragmented (b).
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Treatment of K-BALB tumours in BALB/c nu/nu mice with rSFV-p62-6k VLPs did not result in significant inhibition of growth for these fast-growing tumours, in contrast to previous studies with other slowergrowing tumour cell lines. 13, 14 Immunized nu/nu mice showed a better response than naïve mice at day 15 with treated tumours at 77.7% of the controls compared with 92.7%, but over the total duration of the experiment this difference was not statistically significant (Table 1) .
Immunized BALB/c immunocompetent mice showed an immediate response to treatment with both rSFV-p62-6k VLPs and SFV4. K-BALB tumours swelled to approximately twice their original volume by 24 h postinjection before returning to approximately 4 mm 2 by 48 h postinjection, when the next treatment was administered (Figure 4a ). This phenomenon was consistently observed after each injection. An inhibition in K-BALB tumour growth was then observed with average tumour diameters at day 15 at 43.7% of controls with rSFV-p62-6k treated tumours, and 45.6% with SFV4 treated tumours ( Table 1 ). Most K-BALB tumours began to regrow 5-7 days after cessation of treatment ( Figure  4b ). One mouse from each immunized group showed tumour regression and for the SFV4 treated mouse complete regression was apparant at day 20 before the tumour began to regrow 16 days later. This inhibition of K-BALB tumour growth was significant for both groups compared to the control group (Po0.001), and the SFV4 treatment was more successful than the rSFV-p62-6k VLP treatment (Po0.01).
Naïve BALB/c immunocompetent mice treated with rSFV-p62-6k VLPs or SFV4 did not display the swelling observed in immunized groups until after the third injection ( Figure 4a ). Inhibition of K-BALB tumour growth occurred but not to the same extent as for immunized groups. On day 15, rSFV-p62-6k VLP treated K-BALB tumours had an average diameter of 51.2% of the control tumours while SFV4 treated tumours were 43.8% of controls. Tumours began to regrow by 4-5 days after cessation of treatment. Significant inhibition of K-BALB tumour growth occurred for both groups compared to controls (Po0.001), although there was no significant difference between groups.
CT26 tumours initially responded to treatment in a similar manner to that observed for K-BALB tumours with tumours from immunized groups swelling following the initial injection of rSFV-p62-6k VLPs or SFV4. Naïve groups did not swell until after the third injection ( Figure 4c ). An average CT26 tumour diameter 58.8% of control tumours was observed in naïve mice treated with rSFV-p62-6k VLPs and 56.4% that of controls in naïve mice treated with SFV4 at day 15 following initiation of treatment. In immunized groups at day 15 of treatment, average CT26 tumour diameters of 48.5 and 45% of controls were observed following treatment with rSFVp62-6k VLPs and SFV4, respectively. Following treatment with rSFV-p62-6k VLPs, one CT26 tumour regressed completely in the naïve group (day 27), while three regressed completely in the immunized group (days 18 and 19). SFV4 treatment resulted in no complete regression in the naïve group and the complete regression of two CT26 tumours in the immunized group (day 18), one of which began to regrow on day 27. Unlike K-BALB tumours, no significant difference was noted between CT26 tumours treated with rSFV-p62-6k VLPs and those treated with SFV4 in both immunized and naïve groups. Prior immunization with rSFV-p62-6k VLPs did have a more substantial effect on tumour growth inhibition than that observed in K-BALB tumours, with both CT26 immunized groups showing significant augmentation of the antitumour response in 
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For K-BALB tumours, control mice, both BALB/c and BALB/c nu/nu, were euthanized between days 22 and 25, while mice in rSFV-p62-6k treated groups survived to between days 27 and 40. SFV4 treated groups survived the longest with most mice euthanized between days 29 and 37 and one mouse from the immunized group surviving to day 58. Survival curves were shown to be significantly different with SFV4 treated groups having the most successful response to treatment (Table 1) .
For CT26 tumours, the effect of treatment on survival was more significant, with five mice showing complete regression of the tumour and surviving beyond the experimental period. Immunization had a markedly significant effect on survival, but there was no significant difference between VLP and SFV4 treatment (Table 1) .
Anti-SFV humoral immune response
In order to assess the anti-SFV humoral immune response in BALB/c immunocompetent groups, an ELISA technique was employed which assigned arbitrary anti-SFV units to serum samples by comparison to a reference curve of known positive serum. Mice were sampled in triplicate at days 0, 1, 5, 11, and 15 after initiation of treatment ( Figure 5 ).
Immunized control groups showed a consistently high humoral response to SFV that was maintained for the duration of the experiment. Treatment of tumour-bearing immunized mice with either rSFV-p62-6k VLPs or SFV4 resulted in a slight increase in this already high response. Naïve groups did not show a detectable anti-SFV humoral immune response until day 5 and this was significantly higher in the SFV4 treated group than the rSFV-p62-6k VLP treated group. By day 11 after treatment the humoral immune responses in naïve mice had reached levels comparable with immunized groups.
No detectable anti-SFV humoral immune response was detected in the naïve TNE-treated control group at any stage. BALB/c nu/nu groups were not sampled until the end of the experiment when no significant response was detected (not shown).
Detection of cellular anti-SFV immune responses
In order to assess the cellular immune responses to SFV antigens, splenocyte stimulation assays were performed. Splenocytes were incubated with purified UV-inactivated SFV4 for 72 h and supernatants were harvested and clarified by centrifugation. Capture ELISA was then utilized to measure levels of IFN-g in the supernatants. Naïve control mice maintained stimulation indices below 1.7 while immunized control mice maintained stimulation indices between 6.5 and 10.5 for the duration of the experiment.
Both SFV4 treated and rSFV-p62-6k VLP treated naïve groups gave a peak in IFN-g secretion at day 5 that was followed by a drop at later times. SFV4 treatment resulted in a more sustained response. Immunized groups showed a continual sustained response ( Figure 6 ).
Pathology of paraffin embedded, formalin fixed tumour tissue
Examination of haematoxylin and eosin stained sections of control K-BALB tumours from naïve and immunized mice revealed similar, highly cellular tumours with microvascular proliferation. Early tumours were composed of sheets of spindle cells and tumours older than 11 days were mostly composed of polyhedral cells. Tumour cells were characterized by well-defined cell borders, pale, finely vacuolated cytoplasm and hyperchromatic nuclei with coarsely clumped chromatin and multiple nucleoli (Figure 7a ). Mitotic figures and binucleated forms were common and pleomorphic tumour cells containing multiple nuclei were occasionally observed. Variable-sized areas of necrosis and haemorrhage included fibrin thrombi and aggregates of neutrophils mostly located at the interface with the viable tumour cells (Figure 7b ). Small numbers of neutrophils were loosely distributed in the surrounding connective tissue stroma together with occasional lymphocytes and macrophages in perivascular and perineural locations.
K-BALB tumours from immunized mice treated with SFV4 and rSFV-p62-6k VLPs and sampled at day 1 following treatment were characterized by severe inflammation and necrosis with islands of tumour cells separated by oedema, neutrophils and fibrin (Figure 7d ). Spindle-shaped tumour cells were loosely infiltrated with lymphocytes, macrophages and neutrophils between days 5 and 15 following treatment (Figure 7e ). Plasma cells, clustered in perivascular and perineural locations, frequently contained large, homogeneous eosinophilic inclusions (Russell bodies) (Figure 7g ). Inflammation and necrosis were more severe in SFV4 treated tumours than in rSFV-p62-6k VLP tumours throughout the duration of the experiment. For naïve mice, inflammation and necrosis were most severe Figure 5 Anti-SFV humoral immune responses in mice as determined by anti-mouse IgG ELISA. Units were assigned from a reference curve of known SFV antiserum.
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Immunohistochemistry and immunofluorescence analysis of K-BALB tumours
For immunohistochemistry, sections of formalin-fixed, paraffin embedded K-BALB tumours were utilized for demonstration of CD3, CD45R, and active caspase-3 and frozen tumour sections were utilized for the detection of CD4, CD8, F4/80, and SFV antigens. Double labelling immunofluorescence was utilized for demonstration of SFV antigen together with active caspase-3 or one of the above leucocyte markers in frozen sections.
Cells positive for active caspase-3 were concentrated at the interface between viable tumour cells and areas of necrosis, indicating a possible role for apoptosis in the development of necrosis within the tumours (Figure 7c) . CD45R+, CD3+, CD4+ and CD8+ lymphocytes and F4/80+ macrophages were located primarily in perivascular spaces at the periphery of all tumours with higher numbers in treated tumours than in control tumours (Figure 7i and j) . SFV antigen appeared as granular extracellular deposits in areas of cell debris and was located in macrophages and adjacent to CD8+ lymphocytes in areas of inflammation (Figure 7f and h). For treated tumours, CD3+ cells predominated as the main cellular infiltrate and were located throughout the tumours from day 5 in immunized groups and day 11 in naïve groups. Numbers of CD4+ lymphocytes exceeded numbers of CD8+ positive lymphocytes in treated tumours at day 1 and day 5. Comparable numbers of CD4+ and CD8+ lymphocytes were present throughout the tumours at later time points.
Detection of infectious SFV4 in tumours and brains
K-BALB tumours from days 1, 5, 11 and 15 after SFV4 treatment were sampled in triplicate, homogenized and clarified by centrifugation, and titres of SFV4 determined by plaque assay of resulting supernatants. No virus was detected in any tumour at day 15 whereas all tumours sampled prior to this time were positive for infectious SFV4 with titres typically between 10 4 and 10 5 PFU/mg. No significant difference was noted between naïve and immunized groups.
Brains were sampled from the groups of naïve and immunized mice treated with SFV4 in K-BALB and CT26 studies. All brains from immunized groups were negative for infectious virus. For the two mice in the naïve group that showed clinical signs of SFV4 infection prior to sampling, one was positive for SFV4 replicating virus and one showed brain lesions characteristic of SFV4 infection, which were confirmed positive by immunohistochemistry. Brain samples from all other mice appeared normal. Thus, out of a total of 47 naïve and 47 immunized mice treated with SFV4, only two of the naïve mice showed signs of encephalitis. Mice whose CNS had been infected with SFV4 would have died from encephalitis after showing severe clinical signs. 3 
Discussion
We have previously utilized the inherent ability of rSFV VLPs to induce p53-independent apoptosis in treating human lung carcinoma xenografts (induced by the H358a cell line) in BALB/c nu/nu mice. 12, 13 In a rat prostate cancer cell line overexpressing the bcl-2 oncogene, VLPs expressing the proapoptotic gene bax inhibited tumour growth, but the antitumoral effect was not as effective as that observed in the slower growing H358a xenograpfts.
14 In this study, we used the poorly antigenic K-BALB and CT26 tumour models in immunocompetent BALB/c and athymic BALB/c nu/nu mice. As these tumours are relatively fast-growing, treatment of K-BALB tumours with VLPs in nude mice was ineffective, in contrast to the results obtained previously for the more slowly growing tumours. 13, 14 VLPs expressing the antigenic viral protein E2 (rSFV-p62-6k) were employed in the hope of enhancing the Figure 6 Stimulation indices of splenocytes to SFV4 antigens from mice treated with rSFV-p62-6k VLPs (a) and SFV4 (b). Splenocytes were incubated in triplicate with UV inactivated SFV4 for 72 h and levels of IFN-g secretion were determined by capture ELISA. Stimulation indices were calculated by dividing the average amount of IFN-g in SFV4 stimulated wells by the amount secreted in negative control wells.
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antitumoral effect by recruiting the host immune system. We also examined the feasibility of treating tumours with the replication proficient SFV4 virus.
As the K-ras oncogene is associated with increased resistance to apoptosis induction in some cell types, 25 we investigated whether this was the case with SFV4 and A significant inhibition of tumour growth was observed for both SFV4 and rSFV-p62-6k VLP treated naïve BALB/c mice, which was associated with a strong anti-SFV immune response, detectable by day 5 of treatment. By immunizing mice with rSFV-p62-6k VLPs prior to tumour induction and treatment, this immune response was present from initiation of treatment and the overall inhibition of tumour growth was greater than in naïve groups. Immunization with rSFV-p62-6k VLPs also conferred protection against SFV4, which is pathogenic in mice. 3 No SFV4 virus or lesions associated with SFV4 infection were found in the brains of immunized mice treated with SFV4. Treatment of K-BALB tumours in BALB/c nu/nu mice did not result in effective inhibition of tumour growth for this rapidly growing tumour, so it can be concluded that the host immune system played a major role in the reduction of tumour volume in the immunocompetent groups.
In the presence of an anti-SFV immune response, tumour swelling after treatment was related to inflammation and oedema. This swelling coincided with the detection of humoral and cellular immune responses by ELISA and ex vivo splenocyte stimulation assays, respectively. Multiple treatments were necessary in order to increase the level of cell killing as islands of unaffected tumour cells persisted where the virus or vector had failed to disseminate. It is probable that these areas continued to grow after treatment had ceased, while infected areas were eliminated. It can be concluded that treatment with either rSFV-p62-6k VLPs or SFV4 results in a substantial immune response resulting in massive inflammation and destruction of tumour cells. The presence of large numbers of macrophages and CD4+ lymphocytes among the leucocytic infiltrates indicated that a Th1 inflammatory response played a more significant role in the antitumour response than the Th2 reaction. These findings, together with the observed regression in the phenotype of the tumour cells to a more differentiated spindle cell form following treatment, suggested that the Th1 response also inhibited the rate of tumour cell proliferation. The role of IFN-g and other cytokines in the inhibition of angiogenesis and cellular proliferation in tumours has been previously reported. 32 The development of prototype cancer vaccines and their use in immunotherapy has largely involved exploitation of tumour-associated antigens (TAAs). 33, 34 However, such antigens are associated with only a minority of tumours. Rather than restricting therapy to a specific TAA, utilizing the expression of viral or other antigens to effectively flag tumour cells is a strategy applicable to a much broader spectrum of tumours. Also, in the case of replicating vectors and viruses, the induction of immune responses to viral encoded proteins can be beneficial. 22, 35 This study has shown that even in the presence of a strong anti-SFV immune response, both VLPs and SFV4 were capable of infecting cells at the site of injection and significantly inhibiting tumour growth. Neither the VLPs nor SFV4 were capable of eradicating all the K-BALB tumour cells, even after multiple treatments. The CT26 study yielded more encouraging results, with several tumours from immunized groups completely regressing. This is probably due to the more efficient infection of this cell line by rSFV VLPs and SFV4. Prior vaccination with rSFV-p62-6k VLPs also had a more substantial effect in the CT26 study compared to the K-BALB model. The antitumoural effect could possibly be further enhanced by the introduction of cytotoxic or antiangiogenic factors (including cytokines) into the vector, which would be secreted by cells and diffuse through the tumour. [14] [15] [16] [17] [18] [19] 36 In this study, we have administered VLPs expressing a viral antigen. This could induce a neutralizing immune response that may affect subsequent administrations. This effect could be partially abrogated by the use of VLPs expressing a nonviral antigen such as LacZ. 37 However, such particles would contain viral antigen and may continue to induce a neutralizing immune response. For this study, rSFV-p62-6k VLPs provided a good comparison to the replication proficient SFV4, and administration of such particles was necessary to protect against the possible pathogenic effect of SFV4. Treatment with SFV4 was significantly more successful than with the VLPs, and the cellular immune response was more sustained.
In conclusion, we have shown that the inherent antitumoral activity of the rSFV VLPs and infectious virus was augmented by the expression of SFV viral antigens, and that this effect was further enhanced by immunizing mice prior to tumour induction and treatment. In a clinical situation, it may be possible to utilize VLPs expressing antigens to which a patient already has immunity, or to immunize the patient during an initial phase of conventional chemo-or radiotherapy. In this study, we injected tumours directly with the virus or vector, but it has recently been shown that Sindbis virus, an alphavirus related to SFV, has a natural tropism for tumour cells that could possibly be used for targeting vectors. 38, 39 It is not yet known whether this is also a property of SFV. However, the strategy described in this Treatment of K-BALB and CT26 tumours with SFV JWP Smyth et al study may be useful for the treatment of otherwise incurable tumours that have become resistant to radio-or chemotherapy, by direct injection or perfusion into the tumour.
Materials and methods

Cell culture
The K-BALB (murine sarcoma virus-transformed BALB/3T3) and CT26. WT (colon adenocarcinoma from BALB/c mouse) cell lines were obtained from ATCC and cultured in Dulbecco's minimal essential medium supplemented with 10% foetal bovine serum and antibiotics (streptomycin 100 mg/ml and penicillin 100 U/ml). BHK-21 cells were obtained from ATCC and sBHK cells were a gift from Professor P Liljeströ m (Microbiology and Tumorbiology Center, Karolinska Institute, Stockholm, Sweden). Both cell lines were propagated in BHK-21 medium supplemented with 5% foetal bovine serum, 10% tryptose phosphate broth, 2 mM L-glutamine, 20 mM HEPES, and antibiotics.
Mice
Specific pathogen free female 40-60-day-old BALB/c and BALB/c nu/nu mice were obtained from Harlan (Bicester, UK) and maintained under pathogen-free conditions with sterilized food and water provided ad libitum, in accordance with the principles set down in SI 17/94 of the European Union.
Preparation of rSFV-p62-6k VLPs
The SFV split-helper vector system was obtained from Professor P Liljeströ m and the rSFV-p62-6k construct from Professor H Garoff (Department of Biosciences, Karolinska Institute, Novum, Huddinge, Sweden). VLPs were prepared as previously described 5 with minor alterations. Briefly, BHK-21 cells were cotransfected by electroporation with rSFV-p62-6k RNA and the two helper RNAs: rSFV-CS219A (encoding the capsid protein) and rSFV-HelperS2 (encoding the envelope proteins). The cells were then incubated for 36 h at 331C in 5% CO 2 , the medium containing the VLPs harvested, clarified by centrifugation, aliquoted, and stored at À701C. Titration was performed by infecting monolayers of sBHK cells with serial dilutions of the rSFV-p62-6k VLPs and immunofluorescence carried out using rabbit anti-SFV4 antiserum 18 h postinfection. For in vivo studies, VLPs were concentrated by ultracentrifugation through a 20% w/v sucrose cushion (Beckman SW28 rotor; 28 000 rpm for 2 h at 41C) and resuspended in TNE buffer (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 0.1 mM EDTA).
Preparation of SFV4 virus
The virulent SFV4 strain of SFV (obtained from the infectious clone pSP6-SFV4) was propagated in BHK-21 cells from seed stock and titrated by plaque assay on BHK-21 cells. For in vivo studies the virus was concentrated in the same manner as the VLPs, by ultracentrifugation and resuspension in TNE buffer. H]thymidine (Amersham) was added to appropriate wells 24 h prior to sampling. Upon sampling, monolayers were washed, resuspended in PBS containing 1% sodium dodecyl sulphate, precipitated with glacial 5% trichloroacetic acid, harvested by suction onto filter mats and counted using a liquid scintillation counter.
Cell viability and proliferation analysis
Detection of apoptosis and viral antigen expression in K-BALB cells K-BALB cells were seeded into 24-well cell culture dishes at a concentration of 5 Â 10 4 cells/well and infected in triplicate with medium alone, rSFV-p62-6k VLPs, or SFV4 at a multiplicity of infection of 100. Wells were sampled at 6, 12, 24, 36, 48 , and 72 h postinfection. Cells were incubated with caspase inhibitors conjugated to fluorescein (Oncogene) for 1 h according to the manufacturer's instructions before being trypsinized, washed, fixed, and spun onto slides using a Cytospin III (Shandon). Expression of viral antigen was then detected by immunofluorescence as follows: Cytospin preparations were washed in PBS and blocked using 1.5% normal goat serum (Vector Laboratories) for 30 min at room temperature. Rabbit anti-SFV4 serum was then employed as the primary antibody at a 1:1000 dilution in PBS overnight at 41C. Cytospin preparations were washed twice in PBS Tween (0.05% Tween 20, Merck) followed by PBS and incubated with 0.5% biotinylated goat anti-rabbit immunoglobin (Vector laboratories) in PBS containing 1.5% normal goat serum for 30 min at room temperature. After washing in PBS Tween and PBS again, the cytospin preparations were incubated with rhodamine avidin DCS (Vector Laboratories) at a 1:200 dilution in high-salt buffer (0.5 M NaCl, 10 mM HEPES) for 30 min at room temperature. Slides were then washed twice in high-salt buffer before being dipped in water and mounted using Vectashield mountant with DAPI (Vector Laboratories). Slides were examined using fluorescent microscopy and the percentage positive cells for active caspase (green) and viral antigen (red) were calculated using DAPI (blue) for total cell counts. All cell counts were performed blind.
Treatment of K-BALB and CT26 tumours with rSFV-p62-6k VLPs and SFV4
Groups of five mice were used in all tumour treatment experiments (the minimum number necessary to obtain a statistically significant result). BALB/c nu/nu mice were only used for K-BALB studies and not included in the SFV4 studies as it was assumed that these mice would succumb to SFV4 infection. Those groups to be immunized received an intramuscular (i.m.) injection of 1 Â 10 6 IU of rSFV-p62-6k VLPs in 50 ml TNE in the left tibialis anterior and were boosted 2 weeks later with the same injection in the right tibialis anterior. Remaining cells in 100 ml serum-free DMEM medium. Tumours were measured blind daily using a linear calipers and average tumour diameter was calculated as the square root of the product of two perpendicular measurements, assuming spherical shape. Treatment commenced once tumours had reached an average diameter of 4 mm when they received direct intratumoral injections of 50 ml of TNE buffer alone, TNE buffer containing rSFV-p62-6k VLPs (1 Â 10 10 IU/ml), or TNE buffer containing SFV4 virus (1 Â 10 10 PFU/ml). Tumours were injected every second day with a total of six injections over a 12-day period. Once K-BALB tumours reached 20 mm diameter (approaching 20% of total body weight), mice were euthanized by halothane overdose and cervical dislocation. CT26 tumours became ulcerated if allowed to grow beyond an average diameter of 15 mm and so mice were euthanized as described above once tumours reached this size.
For immunology and pathology, groups of mice were set up as above and sampled in triplicate at days 1, 5, 11 and 15 postinitiation of treatment. Serum and spleens were sampled for detection of humoral and cellular immune responses, respectively. Tumours and brains were also sampled from groups treated with SFV4 for detection of replicating virus, by preparation of a 10% w/v tissue homogenate, clarified by centrifugation, and titrated by plaque assay.
Pathology and immunohistochemistry
Mice were sampled in triplicate at days 1, 5, 11, and 15 postinitiation of treatment for pathological and immunohistochemical examination. Mice were deeply anaesthetized with halothane and perfused through the left ventricle with 10% formal saline for 5 min. After leaving overnight at 41C, tumours (all groups) and brains (in the case of SFV4 treated groups) were excised and processed for paraffin embedding. Sections (3 mm thick) were cut and stained with haematoxylin and eosin (H&E). As many epitopes can be masked or destroyed by formalin perfusion, additional mice were euthanized by halothane overdose and excised tumours were snap-frozen in liquid nitrogen cooled isopentane and stored at À701C for cryosectioning. Spleens and serum were harvested from these mice and utilized for immunological studies (see below).
Detection of tumour infiltrating leucocytes and apoptosis by immunohistochemistry and immunofluorescence
Formalin fixed paraffin embedded sections were rehydrated and quenched for 10 min in PBS containing 3% H 2 O 2 before being subjected to heat-induced epitope retrieval (HIER) in a pressure cooker containing 10 mM citric acid, pH 6.0 and heated to 1211C at 15 psi for 3 min followed by 20 min cooling at room temperature. This method was employed for detection of CD45R and active caspase-3. For detection of CD3, 10 mM EDTA pH 8.0 replaced citric acid as the unmasking buffer. Sections were incubated overnight at 41C with primary antibodies in PBS containing 5% normal rabbit serum (Vector Laboratories) after blocking with 1.5% normal rabbit serum for 30 min at room temperature and blocking endogenous avidin and biotin using the avidin/biotin blocking kit (Vector Laboratories). Rat anti-human CD3 (1:20, NovaCastra) and rat anti-mouse CD45R (1:150, Pharmingen) were used to detect T-and B-lymphocytes, respectively. Rabbit anti-mouse active caspase-3 (1:1000, Cell Signalling Technologies) was used as a primary antibody to detect apoptotic cells; normal goat serum replaced normal rabbit serum in the steps described above. Biotinylated rabbit anti-rat or goat anti-rabbit secondary antibodies (Vector Laboratories) were used appropriately to detect bound primary antibody and the Vector Elite ABC standard HRP kit was then employed according to manufacturer's instructions with 3,3, diaminobenzidine (DAB, Sigma) as substrate and haematoxylin as counterstain. Sections were dehydrated, mounted, and examined using light microscopy for positive (brown) cells.
Snap-frozen sections of tumours were used for immunohistochemical detection of CD8 (1:20, Pharmingen), CD4 (1:20, Pharmingen), F4/80 (1:500, Abcam), active caspase-3 and SFV viral antigen. Sections were stained in the same manner to above excluding the HIER steps. Immunofluorescence was employed replacing the Vectastain HRP step with either rhodamine avidin DCS or fluorecein avidin DCS (Vector Laboratories) in highsalt buffer as described above. Double immunofluorescent labelling was also utilized to stain both viral antigen and active caspase-3, or either in association with the above leucocyte markers. An additional avidin/biotin blocking step was incorporated between each fluorescent labelling procedure when undertaking double labelling. Sections were mounted in Vectashield containing DAPI and examined using fluorescence microscopy. A total of 10 random fields of view were counted per slide, with 20-30 cells in each field, and triplicate slides were counted for each sample.
Detection of humoral immune response
Serum samples were collected from mice sampled on days 1, 5, 11, and 15 postinitiation of treatment, and spleens were also harvested and tumours were snapfrozen (see above). Negative reference serum was prepared by euthanizing five BALB/c mice and harvesting, pooling, aliquoting and storing serum at À701C. Positive reference serum was generated by immunizing 10 BALB/c mice as described previously with rSFV-p62-6k VLPs and challenging 2 weeks postboost with 1 Â 10 6 PFU SFV4 in 500 ml PBS interperitoneally. Mice were then euthanized 3 weeks postchallenge and serum was harvested, pooled, aliquoted and stored at À701C.
An ELISA for the detection of the anti-SFV4 humoral immune responses was employed. Maxisorp ELISA plates (96-well, Nunc) were coated with purified UVinactivated SFV4 in carbonate bicarbonate buffer at 41C. Plates were then washed briefly three times with PBS Tween and blocked using ELISA blocking reagent (Roche) for 15 min at room temperature. After three further washes, serum samples were diluted 1:600 in blocking reagent and applied to the plate in triplicate along with positive and negative reference sera. Reference samples consisting of serial dilutions of positive serum were also included in each plate. Plates were incubated for 1 h at room temperature and washed three Treatment of K-BALB and CT26 tumours with SFV JWP Smyth et al times for 5 min with PBS Tween. HRP-conjugated rabbit anti-mouse IgG (Dako) was then added at a dilution of 1:2000 in blocking reagent to the plates and incubated at room temperature for 1 h. After washing as above, OPD substrate (Sigma) was added and plates were incubated in the dark for 10 min before the addition of 2 N H 2 SO 4 to stop the reaction. Absorbance was read at 492 nm and a reference curve was employed to assign arbitrary anti-SFV4 units (maximum 1000) to each sample. Positive and negative sera acted as controls on each plate to ensure that no plates fell outside a 15% plate-to-plate variance threshold. All samples below 1.5 times the negative control were deemed seronegative and not assigned anti-SFV4 units.
Splenocyte stimulation assay
Triplicate spleens (from days 1, 5, 11, and 15 postinitiation of treatment; see above) were pooled, passed through a cell strainer (Falcon) and red blood cells (RBCs) were lysed using RBC lysis buffer (Biosciences). The resulting splenocyte suspensions were counted and cryopreserved under liquid nitrogen in 90% heatinactivated foetal bovine serum and 10% DMSO. Purified SFV4 was prepared using a sucrose gradient and ultracentrifugation and was UV-inactivated after titration by plaque assay. Thawed splenocytes were counted and incubated (in triplicate) at a concentration of 10 5 cells/ well in 96-well U-bottomed cell culture plates (Nunc) for 72 h in the presence of 5 mg/ml concanavalin A (Sigma), medium alone, or UV-inactivated SFV4 (1 Â 10 5 PFU/ well) in RPMI supplemented with 10% heat-inactivated foetal bovine serum, antibiotics, and 50 mM 2-mercaptoethanol. The OptEIA capture ELISA kit (Pharmingen) for mouse IFN-g was then employed to quantify the levels of this cytokine in the supernatants according to the manufacturers' instructions.
